Peetz Christopher sold $246K of MIRM
Peetz Christopher (CHIEF EXECUTIVE OFFICER) sold 2,602 shares of Mirum Pharmaceuticals, Inc. (MIRM) at $94.64 ($0.25M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a datapoint on insider activity but does not introduce new company fundamentals (no clinical, regulatory, or financial update).
Market read
Traders may monitor for additional insider activity, but this specific filing is unlikely to drive a durable repricing absent other catalysts.
What to watch
10b5-1 plans can still coincide with periods of heightened risk, but this single transaction lacks context on prior sale cadence or total insider activity.
Background
The article is an SEC Form 4 insider transaction disclosure for Mirum Pharmaceuticals, Inc.
Ticker impact
Mirum Pharmaceuticals CEO Peetz sold 2,602 shares in an open-market transaction under a pre-arranged 10b5-1 plan, per SEC Form 4.
Likely minimal near-term impact; any effect would be sentiment-driven and short-lived.
The filing is a routine insider transaction and explicitly states a pre-arranged 10b5-1 plan, which reduces interpretability as a new negative fundamental signal.
Market effects
No direct sector read-through; this is company-specific insider disclosure.
None indicated.
None indicated.
Counterpoint
If follow-on filings show repeated or accelerating insider sales outside normal patterns, traders may re-rate sentiment despite 10b5-1 labeling.
Key entities
- issuerMirum Pharmaceuticals, Inc.
Subject of the SEC Form 4 insider transaction; CEO Christopher Peetz sold shares under a 10b5-1 plan.
- insiderChristopher Peetz
Chief Executive Officer and reporting person; sold 2,602 shares at $94.64 on 2026-06-01.
